BioSpace News Archive

Mevion Medical Systems is pleased to announce it has entered a partnership agreement with Hermes Advanced Therapy Systems Corp. for the distribution of the MEVION S250i Proton Therapy System® in Taiwan and Southeast Asia, including Malaysia, Thailand, and Singapore.

3D BioFibR Inc., an advanced biofibre materials company, announced today it has raised $550,000 to fund development and commercialization of its tissue engineering/biomedical device products and to scale up manufacturing of its novel biofibre-based platform. This investment comes from a consortium of private investors, including $150,000 from Concrete Ventures and $100,000 from Innovacorp. “Completing this s

Matinas BioPharma Holdings, Inc. announced that the independent Data and Safety Monitoring Board of the EnACT study has completed a pre-specified review of the first cohort and unanimously recommended progression to the second cohort of patients.

Syneos Health, the only fully integrated biopharmaceutical solutions organization, announced the Company has been named to the Forbes 2020 list of World’s Best Employers, ranking highest among biopharmaceutical outsourcing organizations.

Medicenna Therapeutics Corp., a clinical stage immuno-oncology company, announced that it will be presenting two abstracts at the EORTC-NCI-AACR Virtual Scientific Program on Molecular Targets and Cancer Therapeutics to be held from October 24 - 25, 2020.

Kamada Ltd., a plasma-derived biopharmaceutical company, announced that it has signed an agreement with the Israeli Ministry of Health to supply its anti-SARS-CoV-2 plasma-derived hyperimmune immunoglobulin product for the treatment of coronavirus patients in Israel.

Aptose Biosciences Inc. announced dosing of the first patient with acute myeloid leukemia in a Phase 1 a/b clinical study with CG-806, the company’s oral kinase inhibitor that potently inhibits the wildtype and mutant forms of FLT3 and BTK, and suppresses select clusters of kinases that drive oncogenic signaling pathways.

CareDx, Inc. announced that it will share the latest data on CareDx products for HLA laboratories at the 46th annual meeting of The American Society for Histocompatibility and Immunogenetics.

ILT2 and ILT4, key myeloid and lymphoid checkpoints, may restrict anti-tumor immunity, enable tumors to evade immune detection and contribute to T cell checkpoint resistance

On track to initiate Phase 1b/2 basket study of etigilimab in combination with an anti-PD-1 in a series of tumor types in Q4 2020